A Targeted Examination of the Clinical Gene Therapy Landscape
In collaboration with key staff and investors from Brammer Bio, our research team conducted a qualitative assessment of the clinical gene therapy landscape in North America, focusing on the commercialization of viral vectors and gene therapy-based vaccines. We identified eight critical therapeutic categories, including both in vivo gene therapy and ex vivo gene-modified cell therapy, that closely aligned with Brammer Bio’s viral vector development and manufacturing expertise. This targeted approach enabled Brammer Bio to refine its sales strategy and build revenue prior to its acquisition by Thermo Fisher.
